Overview of gefitinib in non-small cell lung cancer: an Asian perspective
H Jiang - Japanese journal of clinical oncology, 2009 - academic.oup.com
Clinical experience with the EGFR-TKI gefitinib in Asian patients with NSCLC will be
reviewed, both in patients who have previously failed chemotherapy and in the first-line …
reviewed, both in patients who have previously failed chemotherapy and in the first-line …
Gefitinib in the treatment of advanced non-small-cell lung cancer
M Reck - Expert Review of Anticancer Therapy, 2009 - Taylor & Francis
Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and
their long-term prognosis remains poor, even after platinum-based chemotherapy. EGF …
their long-term prognosis remains poor, even after platinum-based chemotherapy. EGF …
Gefitinib in advanced non‐small cell lung cancer: Clinical experience in patients of Asian origin
A Armour - Asia‐Pacific Journal of Clinical Oncology, 2007 - Wiley Online Library
Abstract Background: The IRESSA Survival Evaluation in Lung cancer (ISEL) trial showed
some improvement in survival which failed to reach statistical significance in the overall …
some improvement in survival which failed to reach statistical significance in the overall …
Management of eGFR-Mutant non-small cell Lung cancer: Focus on Gefitinib
Y Naito, K Goto - Clinical Medicine. Therapeutics, 2009 - journals.sagepub.com
Gefitinib is a first generation, reversible epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI), and EGFR TKIs, such as gefitinib and erlotinib, have yielded dramatic …
kinase inhibitor (TKI), and EGFR TKIs, such as gefitinib and erlotinib, have yielded dramatic …